Bavencio (Avelumab) Market Report 2026

Bavencio (Avelumab) Market Overview

• The Bavencio (Avelumab) market growth in the historic period has been driven by clinical success of immuno-oncology drugs, approval in merkel cell carcinoma • Market expansion is supported by expansion into new tumor indications, increasing global immunotherapy adoption • Growth Driver: Impact Of Rising Cancer Prevalence On The Growth Of The Bavencio (avelumab) Market • Market Trend: Strategic Collaborations For Bavencio (Avelumab) Clinical Trials Expanding Cancer Treatment Potential • North America was the largest region in 2025.

What Is Covered Under Bavencio (Avelumab) Market?

Bavencio (avelumab) is a medication used to treat certain types of cancer. It contains the active ingredient avelumab, a type of immunotherapy that works by helping the body's immune system recognize and attack cancer cells. The main types of indications for bavencio (avelumab) are merkel cell carcinoma, nonsmall cell lung cancer (nsclc), urothelial carcinoma, and gastric cancer. Merkel Cell Carcinoma (MCC) is a rare and aggressive form of skin cancer that originates in the Merkel cells, which are located in the outermost layer of the skin (epidermis). These are administered through various routes of administration such as intravenous, and subcutaneous and are used by various end-users such as hospitals, clinics, and cancer research institutes.

What Is The Bavencio (Avelumab) Market Growth Forecast?

The bavencio (avelumab) market size is expected to see rapid growth in the next few years. It will grow to $1.17 million in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to expansion into new tumor indications, increasing global immunotherapy adoption, growth in oncology clinical trials, improved biomarker driven treatment selection, rising healthcare oncology spending. Major trends in the forecast period include growing adoption of immune checkpoint inhibitors, expansion of pd-l1 targeted therapies, rising use of immunotherapy in solid tumors, combination use with chemotherapy and targeted drugs, increased focus on rare cancer indications.

Global Bavencio (Avelumab) Market Segmentation

1) By Indication: Merkel Cell Carcinoma, Non Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Gastric Cancer 2) By Route of Administration: Intravenous, Subcutaneous 3) By End User: Hospitals, Clinics, Cancer Research Institutes

What Is The Driver Of The Bavencio (Avelumab) Market?

The rising prevalence of cancer is expected to propel the growth of the bavencio (avelumab) market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is due to lifestyle choices such as poor diet and lack of physical activity, increased exposure to environmental pollutants, and advances in diagnostic techniques. Bavencio (avelumab) empowers cancer patients by leveraging its immune checkpoint inhibition mechanism to enhance the body's natural immune response, targeting and destroying cancer cells while offering hope for improved survival and quality of life. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023 and 609,820 cancer deaths in the United States. Therefore, the rising prevalence of cancer drives the bavencio (avelumab) industry.

Key Players In The Global Bavencio (Avelumab) Market

Major companies operating in the bavencio (avelumab) market are Merck & Co. Inc., Pfizer Inc

Global Bavencio (Avelumab) Market Trends and Insights

The key trend in the bavencio (avelumab) market is adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in May 2025, Aulos Bioscience, a US-based immuno-oncology company, partnered with Merck KGaA, a Germany-based science and technology company, for a clinical trial collaboration to study the combination of AU-007, an IL-2 therapeutic, with Bavencio (avelumab) and low-dose aldesleukin. The Phase 2 trial aims to evaluate this combination's potential in treating solid tumors. Bavencio's unique anti-PD-L1 properties, combined with AU-007’s immune-enhancing mechanism, show promise in preclinical trials for eradicating tumors.

What Are Latest Mergers And Acquisitions In The Bavencio (Avelumab) Market?

In March 2023, Merck KGaA, a Germany-based science and technology company, acquired exclusive worldwide rights to the anti-PD-L1 antibody BAVENCIO (avelumab) from Pfizer Inc. for an undisclosed amount. This decision follows the termination of the alliance agreement and Merck's strategy to enhance its leadership in oncology and reflects its commitment to BAVENCIO, which is recognized as a vital treatment option for various cancers, including metastatic Merkel cell carcinoma and advanced renal cell carcinoma. Pfizer Inc. is a US-based pharmaceutical manufacturing company engaged in manufacturing of BAVENCIO (avelumab).

Regional Insights

North America was the largest region in the bavencio(avelumab) market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Bavencio (Avelumab) Market?

The bavencio (avelumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bavencio (Avelumab) Market Report 2026?

The bavencio (avelumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bavencio (avelumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.